Tvardi Therapeutics (TVRD) announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis. The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
- Tvardi Therapeutics initiated with an Outperform at Oppenheimer
- Promising Developments and Strong Financial Position Drive Buy Rating for Tvardi Therapeutics
- Tvardi Therapeutics initiated with a Buy at BTIG
- Tvardi Therapeutics Reports Q1 2025 Financial Results